Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.430
-0.030 (-2.05%)
Nov 13, 2026, 4:00 PM EST - Market closed
Inovio Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 0.3 | 0.07 | 0.22 | 0.83 | 10.26 | 1.77 |
| 0.3 | 0.07 | 0.22 | 0.83 | 10.26 | 1.77 | |
Revenue Growth | 63.93% | -69.99% | -73.83% | -91.89% | 478.24% | -76.05% |
Cost of Revenue | 54.21 | 54.21 | 75.62 | 84.69 | 187.65 | 249.24 |
Gross Profit | -53.91 | -54.14 | -75.4 | -83.86 | -177.39 | -247.47 |
Selling, General & Admin | 32.1 | 32.68 | 37 | 42.88 | 76.19 | 53.75 |
Operating Expenses | 23.67 | 32.68 | 37 | 42.88 | 76.19 | 53.75 |
Operating Income | -77.58 | -86.82 | -112.4 | -126.74 | -253.57 | -301.22 |
Interest Expense | - | - | -0.18 | -1.22 | -1.25 | -1.94 |
Interest & Investment Income | 1.61 | 2.42 | 4.77 | 8.13 | 4.78 | 3.36 |
Earnings From Equity Investments | -2.5 | 0.49 | -1.17 | 0.77 | -4.06 | -0.99 |
Other Non Operating Income (Expenses) | 7.91 | -1.26 | 1.55 | 0.09 | 0.17 | 0.35 |
EBT Excluding Unusual Items | -70.56 | -85.17 | -107.43 | -118.96 | -253.94 | -300.43 |
Impairment of Goodwill | - | - | - | -10.51 | - | - |
Gain (Loss) on Sale of Investments | -0.58 | 0.22 | 0.17 | 1.04 | -11.88 | -3.23 |
Asset Writedown | - | - | - | -1.98 | - | - |
Legal Settlements | - | - | - | -4.7 | -14 | - |
Pretax Income | -71.14 | -84.95 | -107.25 | -135.12 | -279.82 | -303.66 |
Earnings From Continuing Operations | -71.14 | -84.95 | -107.25 | -135.12 | -279.82 | -303.66 |
Net Income | -71.14 | -84.95 | -107.25 | -135.12 | -279.82 | -303.66 |
Net Income to Common | -71.14 | -84.95 | -107.25 | -135.12 | -279.82 | -303.66 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 78 | 47 | 27 | 22 | 20 | 17 |
Shares Outstanding (Diluted) | 78 | 47 | 27 | 22 | 20 | 17 |
Shares Change | 100.45% | 72.63% | 22.49% | 11.51% | 14.27% | 34.62% |
EPS (Basic) | -0.91 | -1.81 | -3.95 | -6.09 | -14.07 | -17.45 |
EPS (Diluted) | -0.91 | -1.81 | -3.95 | -6.09 | -14.07 | -17.45 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -74.41 | -88.92 | -104.56 | -124.69 | -217.18 | -216.94 |
Free Cash Flow Per Share | -0.95 | -1.90 | -3.85 | -5.62 | -10.92 | -12.47 |
Operating Margin | -25953.76% | -132871.32% | -51616.91% | -15233.26% | -2470.93% | -16972.34% |
Profit Margin | -23798.90% | -130000.00% | -49254.27% | -16239.87% | -2726.67% | -17109.87% |
Free Cash Flow Margin | -24894.92% | -136074.45% | -48019.06% | -14986.17% | -2116.34% | -12223.61% |
EBITDA | -76.27 | -85.4 | -110.65 | -123.98 | -249.42 | -297.66 |
D&A For EBITDA | 1.3 | 1.42 | 1.75 | 2.77 | 4.15 | 3.56 |
EBIT | -77.58 | -86.82 | -112.4 | -126.74 | -253.57 | -301.22 |